FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Receptor patents



      
           
This page is updated frequently with new Receptor-related patent applications. Subscribe to the Receptor RSS feed to automatically get the update: related Receptor RSS feeds. RSS updates for this page: Receptor RSS RSS


Electrophotographic image forming apparatus

Date/App# patent app List of recent Receptor-related patents
07/24/14
20140206876
 2-(substituted ethynyl)quinoline derivatives as mglur5 antagonists patent thumbnailnew patent 2-(substituted ethynyl)quinoline derivatives as mglur5 antagonists
Provided is a 2-(substituted ethynyl)quinoline derivative having an mglur5 antagonistic activity and pharmaceutically acceptable salts thereof. The compound of the present invention can be useful as a medicament for treating and preventing mglur5 receptor-mediated diseases such as alzheimer's disease, senile dementia, parkinson's disease, l-dopa-induced dyskinesia, huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, anxiety disorder, depression, neuropathic pain, drug dependence, fragile x syndrome, autism, migraine and gastroesophageal reflux disease (gerd)..
07/24/14
20140206776
 Mrm/srm assay for death receptor 5 protein patent thumbnailnew patent Mrm/srm assay for death receptor 5 protein
Specific peptides, and derived ionization characteristics of those peptides from death receptor 5 (dr5) protein are provided that are particularly advantageous for quantifying the dr5 protein directly in biological samples that have been fixed in formalin by the method of selected reaction monitoring/multiple reaction monitoring (srm/mrm) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
07/24/14
20140206770
 Androgen receptor-dependent gene expression control patent thumbnailnew patent Androgen receptor-dependent gene expression control
Disclosed is the use of at least one amine oxidase inhibitor for modulating the activity of the lysine-specific demethylase (lsd1) in a mammal and to pharmaceutical compositions for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one amine oxidase inhibitor suitable for modulating the activity of the lysine-specific demethylase (lsd1) in a mammal.. .
07/24/14
20140206748
 Compositions and methods related to prostate cancer patent thumbnailnew patent Compositions and methods related to prostate cancer
This disclosure describes markers that can identify patients at risk of developing castration-resistant prostate cancer. The markers, and analyses that use the markers, can be used by health professionals to guide treatment decisions by, for example, helping to evaluate the likelihood that a patient will respond to or develop resistance to prostate cancer therapies targeted to the androgen receptor.
07/24/14
20140206746
 Modulation of growth hormone receptor expression and insulin-like growth factor expression patent thumbnailnew patent Modulation of growth hormone receptor expression and insulin-like growth factor expression
Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-i (igf-i). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor.
07/24/14
20140206739
 Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators patent thumbnailnew patent Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators
The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds.
07/24/14
20140206737
 Application of clonidine hydrochloride as an information intervention agent and an information intervention product and the method of making the same patent thumbnailnew patent Application of clonidine hydrochloride as an information intervention agent and an information intervention product and the method of making the same
This invention relates to a new application of compound clonidine hydrochloride in a use of preparation of information intervention agent, a new preparation method of information intervention agent, and a product. The clonidine hydrochloride interacts with the human information receptor, therefore realizing the intervention through the clonidine hydrochloride information physical method, and treatment was not a chemical treatment.
07/24/14
20140206722
 Methods of use of phenoxypropylamine compounds to treat depression patent thumbnailnew patent Methods of use of phenoxypropylamine compounds to treat depression
Disclosed herein are compositions and methods for treating depression using compositions comprising a compound of formula i. Disclosed herein are compositions and methods for treating depression using compositions comprising phenoxypropylamine compounds and derivatives having selective affinity for and antagonistic activity against the 5-ht1a receptor, as well as 5-ht reuptake inhibitory activity.
07/24/14
20140206714
 Lpa2 receptor-specific benzoic acid derivatives patent thumbnailnew patent Lpa2 receptor-specific benzoic acid derivatives
Disclosed are compounds effective for inhibiting cellular apoptosis and for protecting cells and tissues from the apoptotic effects of chemotherapeutic agents and/or ionizing radiation. Compounds of the invention act as agonists of the lpa2 receptor.
07/24/14
20140206711
 Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use patent thumbnailnew patent Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
07/24/14
20140206707
new patent 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mglur5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
07/24/14
20140206701
new patent Selective subtype alpha 2 adrenergic agents and methods for use thereof
The invention provides well-defined heterocyclic compounds that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with selective subtype modulation of alpha 2 adrenergic receptor..
07/24/14
20140206676
new patent Substituted 4-(1h-pyrazol-4-yl)benzyl analogues as positive allosteric modulators of machr m1 receptors
In one aspect, the invention relates to substituted 4-(1h-pyrazol-4-yl)benzyl analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
07/24/14
20140206672
new patent Thiophenyl and pyrrolyl azepines as serotonin 5-ht2c receptor ligands and uses thereof
The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds.
07/24/14
20140206664
new patent Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof
Heterocycle amino alkyloxy substituted quinazoline derivatives as represented by the structural formula (i) and pharmaceutically acceptable salts thereof, capable of inhibiting the activity of receptor tyrosine kinase egfr, and being used to treat cancers related to the expression of the receptor tyrosine kinase of the erbb family are provided.. .
07/24/14
20140206652
new patent Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
The present invention relates to novel bicyclic methyl amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. .
07/24/14
20140206650
new patent Inhibiting the transient receptor potential a1 ion channel
This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the trpa1 ion channel and/or medical conditions related to trpa1, such as pain and respiratory conditions.. .
07/24/14
20140206649
new patent Cannabinoid receptor modulators
Provided are certain methods useful in the treatment of pain comprising administering a compound of formula ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid cb2 receptor;. .
07/24/14
20140206620
new patent T cell receptors and related materials and methods of use
The invention provides t cell receptors (tcrs) having antigenic specificity for a cancer antigen, e.g., tyrosinase. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, and pharmaceutical compositions.
07/24/14
20140206607
new patent Glucagon/glp-1 receptor co-agonists
Provided herein are peptides and variant peptides that exhibit enhanced activity at the glp-1 receptor, as compared to native glucagon.. .
07/24/14
20140206603
new patent Engineered polypeptide agents for targeted broad spectrum influenza neutralization
The present invention provides novel agents for broad spectrum influenza neutralization. The present invention provides agents for inhibiting influenza infection by bind to the influenza virus and/or hemagglutinin (ha) polypeptides and/or ha receptors, and reagents and methods relating thereto.
07/24/14
20140206549
new patent Method of measuring adaptive immunity
A method of measuring immunocompetence is described. This method provides a means for assessing the effects of diseases or conditions that compromise the immune system and of therapies aimed to reconstitute it.
07/24/14
20140206548
new patent Method of measuring adaptive immunity
A method of measuring immunocompetence is described. This method provides a means for assessing the effects of diseases or conditions that compromise the immune system and of therapies aimed to reconstitute it.
07/24/14
20140206457
new patent Mounting assemblies for a gaming device and associated methods
A mounting bracket includes a substantially planar panel defining a first edge, a second edge opposite the first edge, a first surface, and a second surface opposite the first surface. The substantially planar panel defines a tapered slot open at the first edge, extending from the first edge toward the second edge, and terminating in a slot apex opposite the first edge.
07/24/14
20140206100
new patent Detecting a high molecular weight substance
Label complexes, lateral flow apparatus and methods of detecting a high molecular weight substance are shown and described. In one embodiment, the label complex includes an antispecies antibody and another antibody having sensitivity to both the antispecies antibody and to a control line capture agent, an antibody binding protein and a detectable component.
07/24/14
20140206004
new patent Rationale, methods, and assays for identifying human and non-human primate taste specific genes and use thereof in taste modulator and therapeutic screening assays
This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics.
07/24/14
20140205939
new patent Electrophotographic photoreceptor, process cartridge, and image forming apparatus
An electrophotographic photoreceptor includes a conductive substrate, and a photosensitive layer provided on the conductive substrate, and an outermost surface layer of the electrophotographic photoreceptor is constituted with a polymerized product or crosslinked product of a composition including at least one selected from reactive compounds represented by the formulae (i) and (ii) and a non-reactive charge transporting material, a content of the non-reactive charge transporting material in the composition is from 5% by weight to 40% by weight based on the weight of the outermost surface layer, and a content of the reactive compound before the reaction in the outermost surface layer is 3% by weight or less based on the weight of the outermost surface layer.. .
07/24/14
20140205656
new patent Modified cationic liposome adjuvants
The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the igg sub-type response and enhancing the cd8 response of the liposomal adjuvant. This technology can be used to increase the production of igg2 antibodies.
07/24/14
20140205653
new patent Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (cdn) immune stimulators that activates dcs via a recently discovered cytoplasmic receptor known as sting (stimulator of interferon genes). In particular, the cdns of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce sting-dependent tbk1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure rp,rp or rp,sp stereoisomers, and particularly substantially pure rp,rp, or rpsp cdn thiophosphate diastereomers..
07/24/14
20140205630
new patent Compositions comprising a b subunit of shiga toxin and a means stimulating nkt cells
The present invention relates to a composition comprising a) a b subunit of shiga toxin or a functional equivalent thereof which is able to bind the gb3 receptor, complexed with an antigen and b) at least one ligand of cdl capable of stimulating nk t cells; and to a pharmaceutical composition and a medicament comprising said composition.. .
07/24/14
20140205606
new patent Anti c-met antibodies
The present invention relates to antibodies that specifically bind to the human c-met receptor protein and that act as strict antagonists of hepatocyte growth factor (hgf)-mediated activation of the c-met receptor and also inhibit hgf-independent activation of the human c-met protein.. .
07/24/14
20140205600
new patent Methods of promoting fat loss comprising administering an alk7 inhibitor
The invention relates to alk7 soluble receptors and their uses as antagonists of the function of certain ligands such as gdf-8 (myostatin) and gdf-11. The alk7 soluble receptor of the invention is useful as antagonists of gdf-8 and gdf-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases.
07/24/14
20140205596
new patent Organic compounds
The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer..
07/24/14
20140205595
new patent Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists
It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the growth cycle of non-small cell lung cancer cells.
07/24/14
20140205589
new patent New stable anesthetic composition for reducing skin reactions
A composition is described with reduced degradation rate and/or improved stability of its components. The composition can alleviate or even annihilate cutaneous reactions and can include an emulsion with an oil phase and an aqueous phase, wherein the oil phase can be a eutectic mixture of at least one anesthetic compound and at least one adrenergic receptor agonist.
07/24/14
20140205570
new patent Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases
The subject invention pertains to the use of fractalkine (fkn, cx3cl1) and its receptor cx3cr1 for treatment of neuroinflammation and/or neurodegeneration. In one embodiment, the present invention provides a method for treatment of neuroinflammation and/or neurodegenerative diseases, comprising: administering, to cells of a subject in need of such treatment, an adeno-associated virus that comprises a functional fractalkine gene operably linked to transcriptional control elements.
07/24/14
20140205560
new patent Multimeric il-15 soluble fusion molecules and methods of making and using same
The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (il-15) polypeptide or a functional fragment thereof.
07/24/14
20140205538
new patent Vaccines targeting cellular death receptors
The invention provides therapeutics and methods to induce a mammalian host, including a human, to produce antibodies, which agonize death receptors and cause the apoptotic death of target cells within the host's body. The therapeutics are vaccine compositions, including genetic vaccines encoding death receptor antigens of the tumor necrosis factor receptor family.
07/24/14
20140205321
new patent Electrophotographic image forming apparatus and development cartridge
An electrophotographic image forming apparatus and a development cartridge are provided. The electrophotographic image forming apparatus including a body including an opening, a photoreceptor cartridge attached to, or detached from, the body through the opening, and including a mounting portion, and a development cartridge attached to, or detached from, the mounting portion through the opening while the photoreceptor cartridge is mounted in the body.
07/24/14
20140205318
new patent Electrophotographic image forming apparatus
An electrophotographic image forming apparatus is provided including a body including an opening and a first coupler, a photoreceptor cartridge including a second coupler connected to the first coupler, a first gear connected to the second coupler, and a mounting portion, and attached to or detached from the body through the opening; and a development cartridge including a second gear connected to the first gear and attached or detached from the mounting portion through the opening while the photoreceptor cartridge is mounted in the body.. .
07/24/14
20140205316
new patent Electrophotographic image forming apparatus and development cartridge
An electrophotographic image forming apparatus and development cartridge are provided. The apparatus including a separating member mounted in a development cartridge.
07/24/14
20140205315
new patent Electrophotographic image forming apparatus
An electrophotographic image forming apparatus is provided including a body including an opening, a photoreceptor cartridge attached to, or detached from, the body through the opening and including a mounting portion, a development cartridge attached to, or detached from, the mounting portion through the opening when the photoreceptor cartridge is mounted in the body, and a cover opening or closing the opening and fixing the development cartridge to the mounting portion by pressurizing the development cartridge while the opening is closed.. .
07/24/14
20140205314
new patent Electrophotographic image forming apparatus and development cartridge
An electrophotographic image forming apparatus and a development cartridge are provided. The electrophotographic image forming apparatus includes a body including an opening, a photoreceptor cartridge attached to, or detached from, the body through the opening, a photoconductive drum and a mounting portion, a development cartridge attached to, or detached from, the mounting portion through the opening while the photoreceptor cartridge is mounted in the body, a development roller supplying toner to an electrostatic latent image formed on the photoconductive drum, a cover for opening or closing the opening, and a pressurizing unit fixing the development cartridge to the mounting portion by providing a pressing force to the development cartridge in a direction parallel to a center line connecting centers of the photoconductive drum and development roller while the opening is closed..
07/17/14
20140200277
Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics
Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a trkb receptor molecule..
07/17/14
20140200259
Rnai-mediated inhibition of select receptor tyrosine kinases for treatment of pathologic ocular neovascularization-related conditions
Rna interference is provided for inhibiton of expression of select receptor tyrosine kinase (rtk) targets in ocular neovascularization-related conditions, including those cellular changes resulting from the signal transduction activity of the select rtk targets that lead directly or indirectly to ocular nv, abnormal angiogenesis, retinal vascular permeability, retinal edema, diabetic retinopathy particularly proliferative diabetic retinopathy, diabetic macular edema, exudative age-related macular degeneration, sequela associated with retinal ischemia, and posterior segment neovascularization.. .
07/17/14
20140200244
Phenylethanolamine-based nmda receptor antagonists
Wherein one or more of r1, r2, r3, r4, r5, or the ring formed by the joining of r1 and r2, is a hydrophobic moiety which confers enhanced antagonist activity as compared to existing nmda receptor antagonists, e.g., ifenprodil. Compounds described herein are designed based on the discovery that ifenprodil binds within the allosteric domain of the glun1/glun2b nmda receptor, particularly at the interface between glun1 and glun2b subunits.
07/17/14
20140200240
Methods for determining patient response to anti-platelet aggregation therapy
Diagnostic methods for determining whether an individual will benefit from a particular anti-thrombotic therapeutic agent are disclosed. The methods involve obtaining a biological sample that comprises platelets, from a patient who has been pre-administered a particular therapeutic agent, which is an antagonist of a receptor associated with the biochemical pathways involved in platelet aggregation, and exposing the platelets to an agonist of the receptor.
07/17/14
20140200224
Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
The invention formula r1 is selected from the group consisting of hydrogen, linear c1-c3 alkyl and fluorinated linear c1-c3 alkyl; r2 is hydrogen or methyl; r is selected from the group consisting of hydrogen, halogen, c1-c2-alkyl, fluorinated c1-c2-alkyl, c1-c2-alkoxy and fluorinated c1-c2-alkoxy, r4 is c1-c2-alkyl or fluorinated c1-c2-alkyl; n is 0, 1 or 2, and the physiologically tolerated salts of these compounds and the n-oxides thereof. The invention also relates to a pharmaceutical composition that comprises at least one compound of the formula i and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine d3 receptor antagonists or dopamine d3 agonists, said method comprising administering an effective amount of at least one compound or physiologically tolerated acid addition salt of the formula i to a subject in need thereof..
07/17/14
20140200222
N-linked quinolineamide m1 receptor positive allosteric modulators
The present invention is directed to n-linked quinoline amide compounds of general formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..
07/17/14
20140200215
Lysophosphatidic acid receptor antagonists
Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.. .
07/17/14
20140200211
Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
The present invention is directed to compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism. The compositions include a cholinergic agent, such as a muscarinic acetylcholine receptor m3 agonist, and an alpha agonist having an imidazoline group or a non-steroidal anti-inflammatory agent (nsaid) having cox-2 selectivity.
07/17/14
20140200208
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
The present invention relates to novel triazolo[4,3-a]pyridine derivatives of formula (i) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mglur2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mglur2 subtype of metabotropic receptors is involved.
07/17/14
20140200200
Antagonists of cb1 receptor
The invention relates to an antagonist of cb1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.. .
07/17/14
20140200191
Carbohydrate-lipid constructs and their use in preventing or treating viral infection
The invention relates to selected carbohydrate-lipid constructs and their use as mimics of ligands for receptors expressed by a virus. In particular, the invention relates to the use of selected carbohydrate-lipid constructs in methods of inhibiting virus infection and/or promoting clearance of virus from infected subjects.
07/17/14
20140200190
Novel galactoside inhibitors of galectins
Compounds having an effect as i.a. Galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, wherein the galectin is preferably a galectin-3.
07/17/14
20140200183
Treatment of cardiac arrhythmias
Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (glp-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment..
07/17/14
20140200179
Wnt compositions and methods of use thereof
Wnt compositions and methods for their use are provided. Compositions of the invention comprise fragments of wnt polypeptides having a desired biological activity, which fragments are referred to herein as “mini-wnts”.
07/17/14
20140199717
Multiplex mrm assay for evaluation of cancer
The current disclosure provides specific peptides, and derived ionization characteristics of the peptides from the estrogen receptor (er), progesterone receptor (pr), and/or antigen ki67 (ki67) proteins that are particularly advantageous for quantifying the er, pr, and/or ki67 proteins directly in biological samples that have been fixed in formalin by the method of selected reaction monitoring/multiple reaction monitoring (srm/mrm) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
07/17/14
20140199619
Electrophotographic photoreceptor, method for manufacturing same, and electrophotographic apparatus using same
A layered, positively-charged electrophotographic photoreceptor, a method for manufacturing the photoreceptor and an electrophotographic apparatus using the photoreceptor are disclosed. The layered, positively-charged electrophotographic photoreceptor includes a conductive support on which is provided a sequential stack composed of a charge transport layer containing at least a first hole transport material and a first binder resin; and a charge generation layer containing at least a charge generation material, a second hole transport material, an electron transport material, and a second binder resin, wherein the charge generation layer and the charge transport layer have a total amount of residual solvents that is 50 μg/cm2 or less.
07/17/14
20140199382
Stable pharmaceutical compositions of an s1p receptor agonist
The present invention relates to a stable pharmaceutical composition comprising an s1p receptor agonist and one or more pharmaceutically acceptable excipients, wherein the composition is free of a sugar alcohol. It also relates to method of preparing such compositions and using those compositions in the treatment of multiple sclerosis..
07/17/14
20140199378
New natural and synthetic compounds for treating cancer and other diseases
This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, cns, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti-adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins.
07/17/14
20140199366
Sustained release intraocular implants and methods for treating ocular neuropathies
Biocompatible intraocular implants include a beta adrenergic receptor antagonist and a polymer associated with the beta adrenergic receptor antagonist to facilitate release of the beta adrenergic receptor antagonist into an eye for an extended period of time. The beta adrenergic receptor antagonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.
07/17/14
20140199347
Adjuvant compositions with 4-1bbl
Streptavidin(sa)-4-1bbl and tlr agonists such as monophosphoryl lipid a (mpl) exhibit surprising synergy as adjuvants, inducing immune responses against weak antigens. Accordingly, there are provided adjuvant compositions comprising 4-1bbl and a toll-like receptor (tlr) agonist, such as mpl, methods of inducing an immune response against an antigen in a subject, comprising administering to the subject (a) the antigen, (b) a tlr agonist and, (c) 4-1bbl, and methods of treating a tumor or a cancer in a subject, comprising administering to the subject (a) an antigen associated with the tumor or cancer, (b) a tlr agonist, and (c) 4-1bbl..
07/17/14
20140199320
Modulators of the nlrp3 inflammasome il-1beta pathway for the prevention and treatment of acne
The invention provides inhibitors capable of binding to a member of the inflammasome group comprised of il-1β, il-1 receptor type 1, nlrp3, asc, caspase-1 and cathepsin b with a dissociation constant of 10-8 mol/l or smaller for the prevention and treatment of acne, specifically an antibody, an antibody fragment, an antibody-like molecule, an oligopeptide of 6 to 30 amino acid residues, a nucleic acid aptamer molecule of 10 to 75 nucleotides in length or a soluble polypeptide comprising a contiguous amino acid sequence of at least 30 amino acids comprised within the protein sequence of a member of the group comprised of il-1β, il-1 receptor type 1, il-1 receptor type 2, nlrp3, asc and caspase-1. Similarly, an interfering rna or an antisense modulator of gene expression of il-1β, i l-1β receptor type 1, nlrp3, asc, caspase-1 and cathepsin b are provided for the prevention or treatment of acne..
07/17/14
20140199318
Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in alzheimer's and vascular dementia
The invention relates to means for detecting, binding, removing and/or neutralising agonistic antibodies associated with dementia, preferably alzheimer's disease or vascular dementia.. .
07/17/14
20140199316
Methods of treating complications and disorders associated with g-csf administration
The present embodiments relate to novel uses of mpo inhibitors and inhibitors of mpo and e-selectin binding. In some embodiments, methods are provided for treating g-csf-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits e-selectin receptor/ligand interaction or inhibits mpo activity.
07/17/14
20140199236
Androgen receptor modulator and uses thereof
In the treatment of prostate cancer in combination with other therapeutic options and in the treatment of diseases or conditions that are amenable to treatment with the androgen receptor modulator, as well as pharmaceutical compositions and medicaments that include such compound.. .
07/17/14
20140199233
Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor
The present invention relates to the fabrication and uses of liposomal nanoparticles.. .


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.4793

3433

1 - 1 - 76